RPL21B Antibody

What is RPL21 and why is it significant for research?

RPL21 is a ribosomal protein that forms a component of the 60S subunit of ribosomes. It belongs to the L21E family of ribosomal proteins and plays a crucial role in the assembly of the ribosome and translation of mRNA into proteins . Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit, together composed of 4 RNA species and approximately 80 structurally distinct proteins . Beyond its canonical function in protein synthesis, RPL21 has been implicated in cancer development, particularly in pancreatic cancer, where it may control DNA replication and G1-S phase progression through the regulation of E2F1 transcription factor .

What applications are validated for commercial RPL21 antibodies?

Commercial RPL21 antibodies have been validated for several key applications:

• Immunohistochemistry (IHC): For visualization of RPL21 in tissue sections

• Immunofluorescence (IF): For subcellular localization studies, including confocal microscopy analysis

• Western blotting: For detection and quantification of RPL21 expression levels

When selecting an RPL21 antibody, it's important to verify that it has been validated for your specific application. For instance, the RPL21 Polyclonal Antibody (ABIN7257762) has been validated for immunohistochemistry and immunofluorescence applications with reactivity to human, mouse, and rat samples . Similarly, the RPL21 Rabbit Polyclonal Antibody (CAB14254) has been validated for Western blot applications .

How should I optimize RPL21B antibody dilution for immunofluorescence?

Optimal dilution of RPL21B antibody for immunofluorescence requires careful titration to balance specific signal with background. Based on validated protocols:

• Start with manufacturer's recommended dilution (e.g., 1:200 as used for RPL21 Polyclonal Antibody in HeLa cells)

• Prepare a dilution series (e.g., 1:100, 1:200, 1:500, 1:1000) using appropriate antibody diluent

• Process identical samples with each dilution

• Evaluate results based on:

  • Signal-to-noise ratio

  • Subcellular localization pattern consistency

  • Background fluorescence levels

• Include appropriate controls:

  • Primary antibody omission control

  • Isotype control at the same concentration

  • Positive control sample with known RPL21 expression

The optimal dilution will provide clear specific staining with minimal background. Document your optimization process for reproducibility in future experiments.

What controls should be included when using RPL21B antibodies?

Proper controls are essential for reliable interpretation of RPL21B antibody-based experiments:

For RNA interference experiments targeting RPL21, include both non-targeting siRNA controls and siRNA targeting unrelated genes to distinguish specific from non-specific effects .

How do I validate the specificity of an RPL21B antibody?

Validating RPL21B antibody specificity requires multiple complementary approaches:

• Genetic validation: Use RPL21 siRNA to knock down expression and confirm reduced signal. This approach has been successfully applied in pancreatic cancer cell lines PANC-1 and BxPC-3 .

• Peptide competition assay: Pre-incubate the antibody with the immunogen peptide to block specific binding.

• Multiple techniques validation: Confirm consistent results across different detection methods (e.g., IF, IHC, Western blot).

• Cross-reactivity assessment: Test the antibody on samples from different species to confirm the specified reactivity pattern (e.g., human, mouse, rat) .

• Western blot validation: Verify a single band at the expected molecular weight for RPL21.

• Subcellular localization consistency: For immunofluorescence, confirm the expected localization pattern (primarily ribosomal/nucleolar with some cytoplasmic distribution).

Document all validation steps according to the International Working Group for Antibody Validation (IWGAV) guidelines.

How can RPL21B antibodies be used to investigate its role in cancer biology?

Research has demonstrated that RPL21 plays a significant role in cancer biology, particularly in pancreatic cancer. RPL21B antibodies can be used to investigate this role through several advanced approaches:

• Expression profiling across cancer stages: Use immunohistochemistry with RPL21B antibodies to compare expression levels between normal pancreatic tissue and different stages of pancreatic cancer progression.

• Mechanism investigation: Research has shown that RPL21 siRNA blocks proliferation in pancreatic cancer cells by inhibiting DNA replication and inducing G1 arrest in the cell cycle . RPL21B antibodies can be used to:

  • Monitor changes in RPL21 expression after treatment with potential therapeutic agents

  • Perform co-immunoprecipitation to identify interaction partners in cancer cells

  • Investigate subcellular localization changes during cancer progression

• Pathway analysis: Studies have shown that RPL21 knockdown in pancreatic cancer cells results in downregulation of the mini-chromosome maintenance (MCM) protein family (MCM2-7), CCND1, and CCNE1 . RPL21B antibodies can be used in combination with antibodies against these proteins for multiplex immunofluorescence to visualize pathway dynamics.

• Therapeutic response monitoring: Use RPL21B antibodies to track changes in expression or localization following treatment with therapeutic agents targeting ribosome biogenesis.

The finding that RPL21 siRNA induces apoptosis in cancer cells but not in normal cells suggests RPL21 may be a potential therapeutic target .

What are the optimal protocols for studying RPL21's role in cell cycle regulation?

To investigate RPL21's role in cell cycle regulation, the following optimized protocols can be employed:

• Synchronized cell analysis with immunofluorescence:

  • Synchronize cells at different cell cycle phases (e.g., double thymidine block, nocodazole arrest)

  • Perform dual immunofluorescence with RPL21B antibody and cell cycle markers

  • Quantify nuclear/nucleolar RPL21 levels at different cell cycle stages

  • Protocol details: Fix cells with 4% paraformaldehyde, use RPL21 antibody at 1:200 dilution, counterstain with DAPI

• E2F1 transcriptional activity analysis:
  Research has shown that RPL21 controls DNA replication and G1-S phase progression through regulation of E2F1 transcription factor . To investigate:

  • Perform chromatin immunoprecipitation (ChIP) using antibodies against E2F1

  • Compare E2F1 binding to target promoters in control vs. RPL21-depleted cells

  • Use luciferase reporter assays to measure E2F1 transcriptional activity

• Cell cycle protein expression profiling:

  • Perform Western blot analysis using RPL21B antibodies alongside antibodies against:

    • MCM2-7 family proteins (DNA replication)

    • CCND1 and CCNE1 (G1-S transition regulators)

    • PCNA (proliferation marker)

  • Compare expression patterns before and after RPL21 knockdown

• Flow cytometry cell cycle analysis:

  • Transfect cells with RPL21 siRNA or control siRNA

  • After 24-72 hours, harvest cells for flow cytometry

  • Stain with propidium iodide for DNA content

  • Analyze cell cycle distribution, focusing on G1 arrest phenotype

These protocols should be performed in both cancer cell lines (e.g., PANC-1, BxPC-3) and normal cell lines (e.g., HPDE6-C7) to highlight cancer-specific dependencies .

How can next-generation antibody improvement techniques be applied to RPL21B antibodies?

Next-generation antibody improvement techniques can significantly enhance RPL21B antibody performance for specialized research applications:

• Iterative improvement workflow for RPL21B antibodies:

  • Identify a lead RPL21B antibody with desired properties

  • Elucidate structure-function relationship through epitope mapping

  • Design focused libraries targeting complementarity-determining regions (CDRs)

  • Select improved variants through screening campaigns

• Structure-guided design advantages:

  • Crystal structure determination of antibody-RPL21 complexes can guide optimization

  • Targeted mutagenesis of key residues in CDRs to enhance binding properties

  • Framework optimization to improve stability while maintaining specificity

• Affinity maturation strategies:

  • Apply in vitro selection technologies to increase binding affinity

  • Employ yeast or phage display systems for high-throughput screening

  • Quantitative characterization using surface plasmon resonance (SPR)

• Specificity enhancement approaches:

  • Negative selection against closely related ribosomal proteins

  • Counter-screening to eliminate cross-reactivity

  • Computational design to predict and eliminate off-target binding

These advanced engineering approaches could produce RPL21B antibodies with enhanced properties such as increased sensitivity for detecting low expression levels, improved specificity for distinguishing closely related ribosomal proteins, or special characteristics for particular applications like super-resolution microscopy.

What methodologies are optimal for investigating RPL21's role in apoptosis pathways?

Research has indicated that RPL21 may be involved in caspase-8-related mitochondrial apoptosis . To investigate this role effectively:

• Apoptosis induction and monitoring:

  • Transfect pancreatic cancer cells (PANC-1, BxPC-3) with RPL21 siRNA

  • Include normal pancreatic cells (HPDE6-C7) as controls

  • Analyze apoptosis markers at 24h, 48h, and 72h post-transfection

  • Methods to quantify apoptosis:

    • Annexin V/PI staining with flow cytometry

    • TUNEL assay for DNA fragmentation

    • Western blotting for cleaved caspase-3, cleaved PARP

• Mitochondrial pathway investigation:

  • Measure mitochondrial membrane potential using JC-1 dye after RPL21 knockdown

  • Assess cytochrome c release from mitochondria to cytosol via cell fractionation

  • Examine Bax/Bcl-2 ratio changes by Western blot

• Caspase-8 pathway analysis:

  • Measure caspase-8 activity using fluorogenic substrates

  • Perform inhibitor studies using z-IETD-FMK (caspase-8 inhibitor)

  • Investigate Bid cleavage (connecting extrinsic and intrinsic pathways)

• Dual immunofluorescence approach:

  • Co-stain for RPL21 and mitochondrial markers

  • Track potential translocation of RPL21 to mitochondria during apoptosis

  • Quantify co-localization coefficients

These methodologies should be performed comparatively in cancer versus normal cells, as research has shown that RPL21 siRNA induces apoptosis specifically in cancer cells (BxPC-3, PANC-1) but not in normal cells (HPDE6-C7) , suggesting cancer-specific vulnerability that could be therapeutically exploited.

How can RPL21B antibodies be used in challenging research scenarios like low-expression detection?

Detecting low RPL21B expression levels requires optimized protocols and sensitivity enhancement strategies:

• Signal amplification techniques:

  • Tyramide Signal Amplification (TSA): Can increase detection sensitivity 10-100 fold

  • Quantum dot conjugated secondary antibodies: Provide higher signal-to-noise ratio

  • Proximity Ligation Assay (PLA): For detecting protein interactions at low abundance

• Sample preparation optimization:

  • Extended antigen retrieval: For FFPE tissues, extend heat-induced epitope retrieval time

  • Comparison of different fixatives: Test 4% PFA, methanol, and acetone to determine optimal preservation

  • Permeabilization optimization: Test different detergents (Triton X-100, saponin) and concentrations

• Detection protocol enhancement:

  • Extended primary antibody incubation: Overnight at 4°C to maximize binding

  • Two-step indirect detection: Using biotinylated secondary followed by streptavidin-fluorophore

  • Background reduction: Include additional blocking steps (e.g., with 5% BSA, 5% normal serum)

• Microscopy optimization:

  • Confocal microscopy with increased photomultiplier gain

  • Deconvolution techniques to enhance signal clarity

  • Z-stack acquisition and maximum intensity projection

For challenging tissues or cells with extremely low RPL21 expression, consider RNAscope in situ hybridization as a complementary approach to antibody-based detection.

What are common challenges when using RPL21B antibodies and how can they be addressed?

Researchers working with RPL21B antibodies may encounter several technical challenges that require specific troubleshooting approaches:

For best results, incorporate appropriate controls as discussed in section 1.4 and validate antibody specificity using methods outlined in section 1.5.

How do I distinguish between true RPL21 signal and artifactual staining?

Distinguishing genuine RPL21 signal from artifacts requires systematic validation:

• Expected localization pattern:

  • RPL21 should show strong nucleolar staining with diffuse cytoplasmic signal

  • Ribosomal proteins typically show enrichment in nucleoli and endoplasmic reticulum

  • Unexpected localization patterns should be confirmed with multiple antibodies

• Biological validation:

  • RPL21 siRNA knockdown should reduce signal intensity proportionally to knockdown efficiency

  • Ectopic expression of tagged RPL21 should show co-localization with antibody staining

  • Signal should correlate with known biological functions (e.g., higher in rapidly proliferating cells)

• Technical validation:

  • Secondary antibody-only controls to detect non-specific binding

  • Peptide competition assays to confirm epitope specificity

  • Multiple fixation methods to rule out fixation artifacts

• Comparative analysis:

  • Compare staining patterns across different cell types with known RPL21 expression levels

  • Use multiple antibodies targeting different RPL21 epitopes

  • Compare protein detection with RNA expression (ISH or RT-qPCR)

True RPL21 signal should be reproducible, show expected subcellular distribution, respond to biological manipulations, and correlate with independent measures of RPL21 expression.

What methods can be used to quantify RPL21 expression in tissue samples?

Accurate quantification of RPL21 expression in tissue samples can be achieved through several complementary methods:

• Immunohistochemistry (IHC) quantification:

  • Use standardized IHC protocols with RPL21 antibody

  • Analyze using digital pathology software (e.g., QuPath, HALO)

  • Quantification parameters:

    • H-score (combines intensity and percentage positive cells)

    • Optical density measurements

    • Automated positive cell counting with nuclear/cytoplasmic segmentation

• Multiplex immunofluorescence approaches:

  • Co-stain for RPL21 and cell type-specific markers

  • Use spectral unmixing to separate fluorophore signals

  • Quantify using cell-by-cell analysis in defined tissue regions

• Tissue microarray (TMA) analysis:

  • Create TMAs from multiple patient samples

  • Perform standardized RPL21 IHC on all samples simultaneously

  • Generate quantitative expression data across sample cohorts

• Digital spatial profiling:

  • Combine RPL21 antibody with digital spatial profiling platforms

  • Generate quantitative data with spatial context

  • Correlate with other markers in multiplexed assays

For maximum reliability, normalize RPL21 expression to appropriate housekeeping proteins and include calibration standards when possible. Correlation with complementary mRNA quantification methods (e.g., RNAscope, qRT-PCR) can provide validation of protein-level findings.

How does fixation affect RPL21B antibody performance in different applications?

Fixation methods significantly impact RPL21B antibody performance across applications:

For optimal results with RPL21B antibodies:

• Perform a fixation comparison experiment with your specific antibody and sample type

• Consider dual fixation approaches (e.g., brief PFA followed by methanol) for challenging applications

• Document optimal fixation conditions for each antibody and application

• Always use freshly prepared fixatives and control fixation times precisely

How can I optimize co-immunoprecipitation protocols with RPL21B antibodies?

Successful co-immunoprecipitation (co-IP) with RPL21B antibodies requires careful optimization:

• Lysis buffer optimization:

  • Start with gentle, non-denaturing buffers (e.g., 150mM NaCl, 50mM Tris pH 7.5, 1% NP-40)

  • Include protease/phosphatase inhibitors to preserve interactions

  • Consider ribosome-stabilizing conditions (5-10mM MgCl₂) if studying ribosomal complexes

  • Test different detergent concentrations (0.3-1% NP-40 or Triton X-100)

• Antibody binding conditions:

  • Determine optimal antibody amount (typically 2-5μg per sample)

  • Test different incubation times (2h vs. overnight at 4°C)

  • Consider pre-clearing lysates with protein A/G beads to reduce background

  • Use cross-linking (e.g., DSP) for transient interactions

• Washing stringency balance:

  • Begin with low-stringency washes (lysis buffer)

  • Incrementally increase stringency if background is high

  • Test salt concentration gradient (150-500mM NaCl)

  • Include detergent in wash buffers (0.1-0.5%)

• Elution and detection optimization:

  • Compare different elution methods:

    • SDS sample buffer at 95°C (harsh, disrupts all interactions)

    • Peptide competition elution (gentle, specific)

    • Low pH glycine elution (intermediate stringency)

  • Optimize Western blot detection for interacting partners

For studying RPL21's potential role in cell cycle regulation or apoptosis , include specific controls targeting known interaction partners in the E2F1 pathway or apoptotic machinery, respectively.

How might RPL21B antibodies contribute to understanding the extra-ribosomal functions of RPL21?

Recent research suggests RPL21 has significant extra-ribosomal functions, particularly in cell cycle regulation and apoptosis . RPL21B antibodies can help elucidate these non-canonical roles through:

• Chromatin association studies:

  • Chromatin immunoprecipitation (ChIP) with RPL21B antibodies to identify potential DNA binding sites

  • Sequential ChIP (Re-ChIP) to determine co-occupancy with transcription factors like E2F1

  • Genome-wide mapping of RPL21 chromatin associations using ChIP-seq

• Cell cycle-dependent localization:

  • Track RPL21 localization throughout cell cycle using synchronized cells

  • Monitor potential translocation between nucleolus, nucleoplasm, and cytoplasm

  • Correlate localization with cell cycle regulation events

• Protein complex identification:

  • Immunoprecipitation coupled with mass spectrometry to identify non-ribosomal interaction partners

  • Proximity labeling approaches (BioID, APEX) using RPL21 as bait

  • Investigation of interactions with MCM2-7 proteins and cyclins identified in transcriptome analysis

• Stress response dynamics:

  • Monitor RPL21 behavior during cellular stress conditions

  • Investigate potential stress-specific interactions and functions

  • Compare with other ribosomal proteins with known extra-ribosomal roles

These approaches can help establish whether RPL21 directly participates in transcriptional regulation, DNA replication control, or apoptotic signaling beyond its canonical ribosomal role.

What insights can RPL21B antibodies provide in immune system dysregulation research?

While not directly addressed in the search results, RPL21B antibodies could provide valuable insights into immune system dysregulation based on emerging research on ribosomal proteins:

• Autoantibody studies in autoimmune conditions:

  • Investigate anti-RPL21 autoantibodies in systemic autoimmune diseases

  • Compare RPL21 expression patterns in normal versus inflamed tissues

  • Determine if RPL21 undergoes post-translational modifications during inflammation

• Immune cell activation dynamics:

  • Compare RPL21 expression between resting and activated immune cells

  • Investigate potential non-canonical functions in immune cell differentiation

  • Examine redistribution of RPL21 during immune cell activation

• Inflammatory signaling interactions:

  • Use RPL21B antibodies to investigate potential interactions with inflammatory signaling components

  • Examine co-localization with pattern recognition receptors during immune activation

  • Determine if RPL21 undergoes relocalization during inflammatory responses

• Comparison with recurrent pregnancy loss (RPL) studies:

  • The pro-inflammatory signature observed in recurrent pregnancy loss (RPL) suggests potential links between inflammatory processes and reproductive immunology

  • While representing a different RPL acronym, these studies may provide conceptual frameworks for investigating ribosomal protein dysregulation in inflammatory contexts

Research in this direction could reveal novel roles for RPL21 in immune function and inflammation-related processes.

How can RPL21B antibodies contribute to therapeutic development research?

The finding that RPL21 siRNA induces apoptosis specifically in cancer cells but not normal cells suggests RPL21 as a potential therapeutic target. RPL21B antibodies can contribute to therapeutic development in several ways:

• Target validation studies:

  • Use RPL21B antibodies to confirm differential expression between normal and cancer tissues

  • Investigate correlation between RPL21 expression levels and patient outcomes

  • Perform IHC on tissue microarrays to identify cancer types with RPL21 dependence

• Mechanism of action studies:

  • Track changes in RPL21 expression, localization, and interactions during drug treatment

  • Combine with indicators of DNA replication and cell cycle to monitor functional effects

  • Validate proposed mechanisms involving E2F1, MCM proteins, and cyclin regulation

• Therapeutic antibody development:

  • Apply next-generation antibody development techniques to create functional antibodies

  • Develop antibody-drug conjugates targeting cancer-specific RPL21 accessibility

  • Create internalizing antibodies for targeted delivery to RPL21-dependent cancer cells

• Combination therapy assessment:

  • Use RPL21B antibodies to monitor changes in RPL21 during standard chemotherapy

  • Identify potential synergistic combinations targeting both RPL21 and interacting pathways

  • Investigate whether RPL21 expression correlates with treatment resistance

• Biomarker development:

  • Standardize RPL21 detection for patient stratification

  • Correlate RPL21 expression patterns with response to specific therapies

  • Develop companion diagnostics for RPL21-targeting therapeutics

These approaches leverage the understanding that RPL21 plays crucial roles in cancer cell proliferation and survival through mechanisms distinct from its canonical ribosomal function .

Current state of RPL21B antibody research and applications

RPL21B antibodies have emerged as valuable tools for investigating both the canonical ribosomal functions of RPL21 and its newly discovered roles in cell proliferation, DNA replication, cell cycle regulation, and apoptosis. Current commercial antibodies provide reliable detection in applications including immunohistochemistry, immunofluorescence, and Western blotting , enabling researchers to study RPL21 expression patterns and localization across different cell types and experimental conditions.

The most significant recent finding is that RPL21 appears to play a crucial role in cancer cell proliferation and survival, particularly in pancreatic cancer, where its knockdown inhibits DNA replication, induces G1 arrest, and promotes apoptosis specifically in cancer cells but not normal cells . This cancer-specific vulnerability suggests RPL21 as a potential therapeutic target, and antibodies against RPL21 are essential for further exploring this possibility.

Future directions and emerging technologies

As research into RPL21's diverse functions continues, several promising directions emerge for future RPL21B antibody development and application:

• Development of next-generation antibodies using iterative improvement approaches and structure-guided design to create reagents with enhanced specificity, sensitivity, and application-specific properties.

• Integration of RPL21B antibodies with emerging spatial biology technologies to map RPL21 distribution and interactions at subcellular resolution across tissues and developmental stages.

• Application of RPL21B antibodies in high-throughput screening approaches to identify compounds that modulate RPL21 expression, localization, or function for potential therapeutic development.

• Development of RPL21B antibody-based diagnostics to stratify cancer patients based on RPL21 dependency or expression patterns.

• Expansion of research into additional cancer types beyond pancreatic cancer to determine whether the role of RPL21 in cell proliferation, DNA replication, and apoptosis is broadly applicable across malignancies.